AngioDynamics - Undervalued Gem In Med Tech: Analyst Eyes Stellar Growth With A 'Buy' Stance
Portfolio Pulse from Vandana Singh
H.C. Wainwright initiated coverage on AngioDynamics Inc (ANGO) with a 'Buy' rating and a price target of $19, noting the company's debt-free status and significant undervaluation compared to peers. AngioDynamics, which generates over 80% of its revenue from the U.S., has substantial room for growth in the high-growth Med Tech segment. The company recently sold its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems Inc (MMSI) for $100 million.
September 25, 2023 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merit Medical Systems Inc acquired Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product from AngioDynamics for $100 million.
The acquisition of the Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product could potentially boost MMSI's product offerings and revenue. However, the impact on the stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
AngioDynamics is expected to see growth due to its focus on the high-growth Med Tech segment and recent divestments. The 'Buy' rating and $19 price target from H.C. Wainwright could also boost investor confidence.
The 'Buy' rating and $19 price target from H.C. Wainwright indicate a positive outlook for AngioDynamics. The company's focus on the high-growth Med Tech segment and recent divestments could drive growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100